We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+5.57%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.88B
AUM Growth
-$278M
Cap. Flow
-$105M
Cap. Flow %
-5.61%
Top 10 Hldgs %
47.5%
Holding
84
New
5
Increased
6
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$42.9M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$39.9M
3
PRTA icon
Prothena Corp
PRTA
+$19.3M
4
IMVT icon
Immunovant
IMVT
+$17M
5
ABOS icon
Acumen Pharmaceuticals
ABOS
+$13.6M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$146M
2
ETNB
89bio
ETNB
+$39.8M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$32.5M
4
CABA icon
Cabaletta Bio
CABA
+$6.97M
5
IRON icon
Disc Medicine
IRON
+$5.77M

Sector Composition

Rank Sector Weight
1 Healthcare 98.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
51
Cogent Biosciences
COGT
$6.65B
$5.12M 0.27%
525,000
– –
CNTA
52
DELISTED
Centessa Pharmaceuticals
CNTA
$4.99M 0.27%
770,708
-480,429
-38% -$3.29M
RAPT
53
DELISTED
RAPT Therapeutics
RAPT
$4.99M 0.27%
37,500
– –
THRD
54
DELISTED
Third Harmonic Bio
THRD
$3.33M 0.18%
520,417
-50,000
-9% -$306K
MRSN
55
DELISTED
Mersana Therapeutics
MRSN
$2.54M 0.14%
80,000
+40,000
+100% +$1.9M
EQRX
56
DELISTED
EQRx, Inc. Common Stock
EQRX
$2.22M 0.12%
1,000,000
– –
OBIO icon
57
Orchestra BioMed
OBIO
$238M
$2.08M 0.11%
238,193
-11,807
-5% -$79.4K
TSVT
58
DELISTED
2seventy bio
TSVT
$1.8M 0.1%
459,836
– –
BDTX icon
59
Black Diamond Therapeutics
BDTX
$96.8M
$1.45M 0.08%
506,000
-1,508,858
-75% -$5.56M
DBVT
60
DBV Technologies
DBVT
$799M
$1.34M 0.07%
98,510
-46,490
-32% -$729K
BCAB icon
61
BioAtla
BCAB
$5.46M
$1.17M 0.06%
13,727
– –
KOD icon
62
Kodiak Sciences
KOD
$2.6B
$1.08M 0.06%
+600,000
New +$2.12M
FATE icon
63
Fate Therapeutics
FATE
$286M
$1.06M 0.06%
500,000
– –
RAIN
64
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$993K 0.05%
1,152,212
– –
MIST icon
65
Milestone Pharmaceuticals
MIST
$138M
$958K 0.05%
309,007
-389,854
-56% -$1.21M
VRCA icon
66
Verrica Pharmaceuticals
VRCA
$89.7M
$649K 0.03%
+16,696
New +$848K
BCEL
67
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$575K 0.03%
2,202,333
– –
NGM
68
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$535K 0.03%
500,000
– –
THRX
69
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$404K 0.02%
150,000
-200,000
-57% -$784K
TARA icon
70
Protara Therapeutics
TARA
$220M
$349K 0.02%
209,227
– –
TCRT icon
71
Alaunos Therapeutics
TCRT
$4.59M
$145K 0.01%
7,333
-2,667
-27% -$115K
NUVB.WS
72
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$26.7K ﹤0.01%
266,666
– –
SRZNW icon
73
Surrozen Inc Warrant
SRZNW
$69.7K
$2.75K ﹤0.01%
66,666
– –
CABA icon
74
Cabaletta Bio
CABA
$437M
– –
-540,000
Closed -$6.97M
ETNB
75
DELISTED
89bio
ETNB
– –
-2,100,000
Closed -$39.8M
1 2
3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Boxer Capital held 84 positions worth $1.88B, down 13% from $2.16B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Boxer Capital withdrew a net $105M in Q3 2023, closing 11 positions and reducing 10 holdings. Its most notable exit was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $146M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

Against the trend, Boxer Capital opened a new position in State Street SPDR S&P Biotech ETF worth $36.5M.

  • Boxer Capital's largest Q3 2023 buy was State Street SPDR S&P Biotech ETF: 500,000 shares worth $36.5M.
  • Boxer Capital added most to Mirati Therapeutics, Inc. Common Stock in Q3 2023, an estimated $42.9M increase.
  • Boxer Capital's biggest Q3 2023 reduction was Black Diamond Therapeutics, cutting an estimated $5.56M.
  • Boxer Capital fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $146M.
  • Boxer Capital's ten largest holdings make up 47% of its $1.88B portfolio in Q3 2023.
  • Boxer Capital opened 5 new positions and closed 11 in Q3 2023.
  • Boxer Capital's portfolio value fell 13% quarter-over-quarter to $1.88B.

Based on Boxer Capital's 13F filing for Q3 2023, filed 14 Nov 2023.